Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact

Resources

The latest in immuno research, from the discovery & development of cell & antibody therapies through to omics-based approaches and clinical case studies

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Read Now
Therapeutic Modalities

Positive Results from iNKT Cell Therapy Clinical Trial for COVID-19 ARDS

The small exploratory trial shows signs that iNKT cells can improve the survival rate of respiratory distress from COVID-19.
Read More
Therapeutic Modalities

How to Improve Therapeutic Efficacy: Safety Considerations in Oncolytic Virotherapy

Oncolytic virotherapy targets cancer cells with viruses, promising personalized treatment with minimal side effects. Safety measures include minimizing off-target effects and systemic spread. Combining with immunotherapy enhances efficacy, revolutionizing cancer treatment.
Read More
Therapeutic Modalities

Zika Virus Tested as an Effective Oncolytic Agent for Glioblastoma in In Vitro Models

More results are in for the oncolytic potential of the Zika virus, where it has proven effective against the most common form of brain cancer in vitro.
Read More
Therapeutic Modalities

Post-Event Proceedings – Immuno 2023

Concise and insightful summaries of presentations delivered by prominent thought leaders at Immuno 2023.
Read More
Therapeutic Modalities

In Vivo Models Show Survival Promise for Zika Oncolytic Viral Therapy for Neuroblastoma

One of the deadliest cancers in children could have its survival rate improved by the advent of new research into the oncolytic effect of Zika virus.
Read More
Therapeutic Modalities

Experiments Link Gut Microbiome and Graft-versus-Host Disease

Modulating the gut microbiome may be a key to preventing GvHD and stopping relapse.
Read More
Therapeutic Modalities

UPenn Medicine Presents Promising Phase I CAR T Trial with Novel Binding Mechanism

The CAR T therapy targets CD19 closer to the cell membrane and has demonstrated remarkable efficacy in its Phase I clinical trial.
Read More
Therapeutic Modalities

Immunostimulatory Oncolytic Viruses: Interview with Angelica Loskog, CEO, Lokon Pharma

Diving deep into Lokon Pharma's immunostimulatory oncolytic virus programme. Learn about their LOAd platform, transition to the clinic, and more.
Read More
Therapeutic Modalities

Bispecific Antibody Format: Interview with Laura von Schantz, Chief Technology Officer, Alligator Biosciences

Talking with Laura von Schantz, Chief Technology Officer, at Alligator Biosciences about their RUBY bispecific antibody format.
Read More
Therapeutic Modalities

Monitoring Cell – Attachment and Tightjunctions in the Same Assay

Nanion Technologies GmbH, Munich. University of Regensburg, Regensburg.
Read More
Therapeutic Modalities

SomaScan Panels

Big Insights. Targeted Data. Consistent Results.
Read More
Therapeutic Modalities

SomaScan®Assay v4.1

The SomaScan Platform is a powerful tool with applications in scientific research and health and wellness.
Read More

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things immuno